Please assess the completion status of the following clinical trial:

Trial Title: ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients electing to undergo primary or revision total hip or knee arthroplasty~* Currently taking an ACE-I~Exclusion Criteria:~* Trauma patients~* Immunosuppressed patients (HIV/AIDS, organ transplant recipients, chemotherapy patients, chronic steroid use)~* Patients with history of severe hypertension related illness such as hypertension associated with stroke or myocardial infarction~* Patients in who continuation of their ACE-I is expressly mandated by their prescribing physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuation Group (Type: EXPERIMENTAL): Subjects randomized to this group will continue their ACE-I through the day of surgery
- Cessation Group (Type: EXPERIMENTAL): Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose \>48 hours prior to surgery)

Based on this trial design, predict the completion outcome and termination type (if applicable).